Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
ALS Data For Verdiperstat Expected In 2022
Executive Summary
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
You may also be interested in...
Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.